Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey
Cardoso F, Rihani J, Harmer V, Harbeck N, Casas A, Rugo HS, Fasching P, Moore A, de Courcy J, Pathak P, Haftchenary S, Aubel D, Schumacher-Wulf E (2023)
Publication Type: Journal article
Publication year: 2023
Journal
Book Volume: 28
Pages Range: 856-865
Journal Issue: 10
Abstract
BACKGROUND: Quality of life (QOL) is a critical factor in decision-making for advanced breast cancer (ABC). There is a need to improve how QOL and treatment-related side effects (SEs) that impact it are clinically assessed. We examined healthcare professionals' (HCPs') and patients' perspectives on the importance of QOL discussions and the impact of SEs on QOL in clinical settings. PATIENTS AND METHODS: A cross-sectional online survey was conducted (7/2020-5/2021) among oncologists, nurses, and patients with HR+/HER2- ABC in 7 countries. RESULTS: The survey was completed by 502 HCPs and 467 patients. Overall, 88% of oncologists and 49% of patients recalled QOL discussions at follow-up. In the first- through fourth-line (1L, 2L, 3L, and 4L) settings, respectively, 48%, 57%, 79%, and 85% of oncologists reported QOL was very important; 73% and 45% of patients receiving 1L and 2L treatment and 40% receiving 3L+ treatment indicated QOL was important. Patients reported that insomnia, anxiety, back pain, fatigue, diarrhea, hot flashes, low sexual interest, and loss of appetite had a moderate/severe impact on QOL. Of patients experiencing certain SEs, ≥64% did not discuss them with HCPs until there was a moderate/severe impact on QOL. In patients receiving a CDK4/6 inhibitor, SEs, including insomnia, diarrhea, back pain, and fatigue, had a moderate/severe impact on QOL. CONCLUSIONS: This survey discovered disconnects between HCPs and patients with ABC on the importance of QOL discussions and the impact of SEs on QOL. These data support the use of ABC-specific QOL questionnaires that closely monitor SEs impacting QOL.
Authors with CRIS profile
Involved external institutions
Champalimaud Foundation / Fundação Champalimaud
Portugal (PT)
Imperial College Healthcare NHS Trust
United Kingdom (GB)
Klinikum der Universität München
Germany (DE)
Hospitales Universitarios Virgen Macarena y Virgen del Rocío
Spain (ES)
UCSF Helen Diller Family Comprehensive Cancer Center
United States (USA) (US)
Adelphi Real World
United Kingdom (GB)
Novartis AG
Switzerland (CH)
Mamma Mia! Das Brustkrebsmagazin
Germany (DE)
Portugal (PT)
Imperial College Healthcare NHS Trust
United Kingdom (GB)
Klinikum der Universität München
Germany (DE)
Hospitales Universitarios Virgen Macarena y Virgen del Rocío
Spain (ES)
UCSF Helen Diller Family Comprehensive Cancer Center
United States (USA) (US)
Adelphi Real World
United Kingdom (GB)
Novartis AG
Switzerland (CH)
Mamma Mia! Das Brustkrebsmagazin
Germany (DE)
How to cite
APA:
Cardoso, F., Rihani, J., Harmer, V., Harbeck, N., Casas, A., Rugo, H.S.,... Schumacher-Wulf, E. (2023). Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey. Oncologist, 28(10), 856-865. https://doi.org/10.1093/oncolo/oyad207
MLA:
Cardoso, Fatima, et al. "Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey." Oncologist 28.10 (2023): 856-865.
BibTeX: Download